



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugalsky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Jeffery T. Helvey  
Heidi L. Kraus  
Crystal D. Sayles  
Edward W. Yee  
Albert L. Ferro  
Donald R. Banowitz  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Albert J. Fasulo II  
Eldora Ellison Floyd  
W. Russell Swindell

Thomas C. Fiala  
Brian J. Del Buono  
Virgil Lee Beaston  
Reginald D. Lucas  
Kimberly N. Reddick  
Theodore A. Wood  
Elizabeth J. Haanes  
Bruce E. Chalker  
Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Uhler  
Rae Lynn Pongaman  
Jane Shershenovich  
Lawrence J. Carroll

Senior Counsel  
Samuel L. Fox  
Kenneth C. Bass III

Registered Patent Agents  
Karen R. Markowicz  
Andrea J. Kamage  
Nancy J. Leith  
Joseph M. Conrad III  
Ann E. Summerfield  
Helene C. Carlson  
Gaby L. Longworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Angelique G. Uy  
Boris A. Matvenko  
Mary B. Tung

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Admitted only in Texas

July 9, 2002

Corres. and Mail  
**BOX AF**

WRITER'S DIRECT NUMBER:  
(202) 371-2615  
INTERNET ADDRESS:  
FRANKC@SKGF.COM

Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**  
JUL 12 2002  
TECH CENTER 1600/2900

Re: U.S. Utility Patent Application  
Appl. No. 09/380,203; 102(e) Date: April 25, 2000  
For: **Transgenic Animals and Cell Lines for Screening Drugs Effective for  
the Treatment or Prevention of Alzheimer's Disease**  
Inventors: de la Monte *et al.*  
Our Ref: 0609.4370001/RWE/FRC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Amendment and Reply Under 37 C.F.R. § 1.116;
2. Copy of Information Disclosure Statement (*filed December 3, 1999*);
3. Copy of the listing of the cited documents on Form PTO-1449 (5 pages) (*filed December 3, 1999*);
4. Copy of each of the twenty-four (24) cited documents listed on Form PTO-1449 (*filed December 3, 1999*);
5. Copy of the PTO return postcard date-stamped December 3, 1999; and
6. Return Postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are

Commissioner for Patents  
July 9, 2002  
Page 2

necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Frank R. Cottingham  
Attorney for Applicants  
Registration No. 50,437

FRC/pcd  
Enclosures

::ODMA\MHODMA\SKGF\_DC1;32149;1

Applicants: de la Monte *et al.*

Application No.: 09/380,203

Int'l Filing Date: February 26, 1998

For: Transgenic Animals and Cell Lines for Screening Drugs Effective for the Treatment or Prevention of Alzheimer's Disease

Art Unit: To Be Assigned

Examiner: To Be Assigned

Docket: 0609.4370001


Atty: RWE/KKV



RECEIVED  
JUL 12 2002  
TECH CENTER 1600/2900

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 37 U.S.C. § 371 (*in duplicate*);
2. Information Disclosure Statement;
3. A listing of the cited documents on Form PTO-1449 (5 sheets); and
4. A copy of each of the cited documents (25).



Please Date Stamp And Return To Our Courier